Latest Breaking News On - Seres therapeutics daily - Page 1 : comparemela.com

Oppenheimer Cuts Seres Therapeutics (NASDAQ:MCRB) Price Target to $4 00

Oppenheimer Cuts Seres Therapeutics (NASDAQ:MCRB) Price Target to $4 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Seres therapeutics incRafferty asset managementVanguard group incSeres therapeuticsFree reportChardan capitalGet free reportBay capital managementAsset managementSeres therapeutics daily

Oppenheimer Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $4 00

Oppenheimer Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $4 00
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Seres therapeutics incTower research capitalCommonwealth equity servicesMirae asset global investments coArete wealth advisorsSeres therapeuticsGet free reportChardan capitalEquity servicesWealth advisorsResearch capitalAsset global investmentsQuantbot technologiesSeres therapeutics daily

Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday

Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Seres therapeutics incSeres therapeuticsGet free reportTherapeutics trading downSeres therapeutics daily

Seres Therapeutics (MCRB) to Release Earnings on Wednesday

Seres Therapeutics (MCRB) to Release Earnings on Wednesday
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Seres therapeutics company profileSeres therapeutics incSeres therapeuticsGet free reportTherapeutics stock downSeres therapeutics daily

Seres Therapeutics, Inc (NASDAQ:MCRB) Given Average Rating of Moderate Buy by Analysts

Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has earned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […]

Seres therapeutics incE fund management coProshare advisorsRoyal bankFund management coPricet rowe associates incSeres therapeuticsGet free reportMarketbeat ratingsFund managementShare advisorsPricet rowe associatesGet freeSeres therapeutics dailyNasdaq mcrb